Company Information

  

Address: 121 SEAPORT BOULEVARD  
City: BOSTON 
State: MA 
Zip Code: 02210 
Telephone: 475-230-2596 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. We are the global leader in complement inhibition and have developed and commercialize the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/20186.22NA17.92
12/20171.97NA60.71
09/20172.24NA62.63
06/20172.31NA52.67
03/20172.10NA57.73
12/20161.76NA69.52
09/20161.65NA74.27
06/20160.30NA389.20

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity0.07Total Liab/Total Assets0.35
Net Inc/Total Assets0.03Total Liab/Inv Cap0.38
Net Inc/Inv Cap0.04Total Liab/Comm Equity0.70
Pretax Inc/Net Sales0.15Interest Coverage Ratio6.57
Net Inc/Net Sales0.12Curr Debt/Equity0.02
Cash Flow/Net Sales0.31LTD/Equity0.34
SG&A/NetSales0.32Total Debt/Equity0.36
Asset Utilization   Liquidity  
Net Receivables Turnover5.16Quick Ratio2.62
Inventory Turnover1.09Current Ratio3.10
Inventory Day Sales0.00Net Rec/Curr Assets0.25
Net Sales/Work Cap1.77Inv/Curr Assets0.16
Net Sales/PP&E2.68  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 930.90 910.10 859.00 912.40
Cost of Goods Sold 91.60 144.20 157.00 84.00
Selling & Admin Exps 309.80 305.40 275.00 289.70
Operating Income 267.40 109.40 80.00 226.00
Interest Exp 24.10 25.40 25.00 24.50
Pretax Income 351.60 89.80 58.00 206.00
Other Income 108.30 5.80 3.00 4.50
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 249.10 30.30 78.00 164.90

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 1,590.90 1,474.10 1,529.00 1,444.00
Receivables - Total 776.70 726.50 705.00 710.00
Inventories - Total 456.50 460.40 441.00 410.00
Total Current Assets 3,152.00 2,953.90 2,882.00 2,789.00
Net Property, Plant & Equipment 1,379.30 1,325.40 1,354.00 1,233.00
Total Assets 13,830.20 13,583.30 13,643.00 13,489.00
Liabilities        
Accounts Payable 639.90 710.20 738.00 613.00
Debt in Current Liabilities 167.50 167.40 167.00 167.00
Total Current Liabilities 942.00 952.50 972.00 856.00
Long-Term Debt 3,029.00 3,063.60 3,096.00 3,081.00
Total Liabilities 4,717.50 4,690.20 4,699.00 4,614.00
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings 2,497.40 2,242.10 2,212.00 2,134.00
Treasury Stock -1,689.90 -1,604.90 -1,440.00 -1,380.00
Total Stockholders' Equity 9,112.70 8,893.10 8,944.00 8,875.00
Total Liabilities and Stockholders' Equity 13,830.20 13,583.30 13,643.00 13,489.00

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities 299.30 257.60 270.00 280.10
Net Cash Provided by Investing Activities -254.70 0.70 -171.00 -252.70
Net Cash Provided by Financing Activities -123.50 -225.60 -95.00 -207.30

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20131,551.35252.901.27
12/20142,234.00657.003.26
12/20152,604.00144.400.67
12/20163,084.10399.401.76
12/20173,551.10443.301.97
Growth Rates23.0015.0611.60

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18669209,84494.31




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.